ORIC.OQ
Latest Trade
21.33USDChange
--(--)Today's Range
-
--52 Week Range
-
40.60As of on the NASDAQ ∙ Minimum 15 minute delay
March 23 (Reuters) - Oric Pharmaceuticals Inc <ORIC.O>::ORIC PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2020 FINANCIAL RESULTS AND OPERATIONAL UPDATE.ORIC PHARMACEUTICALS INC - QTRLY NET LOSS PER SHARE, BASIC AND DILUTED $0.84.
Jan 11 (Reuters) - Oric Pharmaceuticals Inc <ORIC.O>::ORIC PHARMACEUTICALS PROVIDES CORPORATE UPDATE AND HIGHLIGHTS KEY 2021 MILESTONES.ORIC PHARMACEUTICALS INC - THREE IND/CTA FILINGS FOR ORIC-533, -944, AND -114 EXPECTED IN 2021.ORIC - LEAD PROGRAM ORIC-101 CONTINUES ENROLLMENT INVESTIGATING TWO THERAPEUTIC MECHANISMS OF ACTION, ON TRACK FOR TWO INITIAL DATA READOUTS IN 2021.ORIC PHARMA- CO EXPECTS ITS CASH, CASH EQUIVALENTS & MARKETABLE SECURITIES WILL BE SUFFICIENT TO FUND CURRENT OPERATING PLAN INTO SECOND HALF OF 2023.
Nov 10 (Reuters) - Oric Pharmaceuticals Inc <ORIC.O>::ORIC PHARMACEUTICALS INC FILES FOR OFFERING OF UP TO 4.0 MILLION SHARES OF COMMON STOCK - SEC FILING.
Nov 10 (Reuters) - Oric Pharmaceuticals Inc <ORIC.O>::ORIC PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.SAYS OFFERING 4.00 MILLION COMMON SHARES.
Nov 5 (Reuters) - Oric Pharmaceuticals Inc <ORIC.O>::QTRLY LOSS PER SHARE $0.84.ORIC PHARMACEUTICALS - EXPECTS CURRENT CASH, CASH EQUIVALENTS,MARKETABLE SECURITIES WILL BE SUFFICIENT TO FUND CURRENT OPERATING PLAN INTO H2 OF 2022.CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES TOTALED $186.6 MILLION AS OF SEPTEMBER 30, 2020.Q3 EARNINGS PER SHARE VIEW $-0.39 -- REFINITIV IBES DATA.
Oct 19 (Reuters) - Oric Pharmaceuticals Inc <ORIC.O>::ORIC PHARMACEUTICALS EXPANDS PRECISION ONCOLOGY PIPELINE WITH EXCLUSIVE LICENSE TO BRAIN PENETRANT EGFR/HER2 EXON 20 INHIBITOR PROGRAM.ORIC PHARMACEUTICALS INC - INITIATION OF GLOBAL PHASE 1/2 TUMOR-AGNOSTIC TRIAL IN GENETICALLY DEFINED CANCERS EXPECTED IN SECOND HALF OF 2021.ORIC PHARMACEUTICALS INC - ENTERED INTO AN EXCLUSIVE LICENSE AGREEMENT WITH VORONOI, INC..ORIC - SECURED EXCLUSIVE RIGHTS WORLDWIDE EXCLUDING CHINA, HONG KONG, MACAU AND TAIWAN FOR DEVELOPMENT AND COMMERCIALIZATION OF ORIC-114.ORIC PHARMACEUTICALS - IF ORIC PURSUES SECOND LICENSED PRODUCT, ORIC WOULD PAY VORONOI UP TO ADDITIONAL $272 MILLION IN SUCCESS-BASED MILESTONES.ORIC PHARMACEUTICALS INC - WILL ALSO PAY TIERED MID-SINGLE-DIGIT TO LOW DOUBLE-DIGIT ROYALTIES BASED ON ANNUAL NET SALES IN ORIC TERRITORY.
Oct 9 (Reuters) - Oric Pharmaceuticals Inc <ORIC.O>::ORIC PHARMACEUTICALS ANNOUNCES PRESENTATION OF PRECLINICAL DATA ON GLUCOCORTICOID RECEPTOR ANTAGONIST OVERCOMING RESISTANCE TO AN ANDROGEN RECEPTOR DEGRADER AT THE 32ND EORTC-NCI-AACR SYMPOSIUM 2020.ORIC PHARMACEUTICALS INC - EXPECTS TO REPORT INTERIM DATA FROM ONE OF TRIALS IN FIRST HALF OF 2021 AND FROM OTHER TRIAL IN SECOND HALF OF 2021.
Aug 5 (Reuters) - Oric Pharmaceuticals Inc <ORIC.O>::ORIC PHARMACEUTICALS REPORTS SECOND QUARTER 2020 FINANCIAL AND OPERATIONAL UPDATE.ORIC PHARMACEUTICALS INC QTRLY LOSS PER SHARE $0.51.ORIC PHARMACEUTICALS - EXPECTS CURRENT CASH AND CASH EQUIVALENTS WILL BE SUFFICIENT TO FUND CURRENT OPERATING PLAN INTO Q4 OF 2022.
May 20 (Reuters) - Oric Pharmaceuticals Inc <ORIC.O>::ORIC PHARMACEUTICALS REPORTS FIRST QUARTER 2020 FINANCIAL AND OPERATIONAL RESULTS.ORIC PHARMACEUTICALS INC QUARTERLY LOSS PER SHARE $4.46.ORIC PHARMACEUTICALS INC SAYS CASH AND CASH EQUIVALENTS OF $204.2 MILLION AS OF APRIL 30, EXPECTED TO FUND CURRENT OPERATING PLAN INTO 2023.
May 1 (Reuters) - Orbimed Advisors Llc::ORBIMED ADVISORS LLC REPORTS 9.2% STAKE IN ORIC PHARMACEUTICALS INC AS OF APRIL 28 - SEC FILING.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.